# Effectiveness of Rituximab in Pediatric OMS Patients.

> **NCT00244361** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Pediatric Neuroinflammation Organization, Inc.** · enrollment: 25 (actual)

## Conditions studied

- Opsoclonus-myoclonus Syndrome
- Opsoclonus
- Myoclonus
- Ataxia

## Interventions

- **DRUG:** rituximab

## Key facts

- **NCT ID:** NCT00244361
- **Lead sponsor:** National Pediatric Neuroinflammation Organization, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2011-05-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00244361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00244361, "Effectiveness of Rituximab in Pediatric OMS Patients.". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT00244361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*